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ABSTRACT
Aims The clinical signiﬁcance of TOP2A as a prognostic
marker has not been clariﬁed. The aims of this study
were to investigate the frequency of TOP2A copy number
change; to correlate TOP2A with HER2 status, hormone
receptor (HR) status and molecular subtype, and further
to explore differences in breast cancer-speciﬁc survival
according to TOP2A and HER2.
Methods In this study, TOP2A, HER2 and chromosome
17 copy number were assessed in 670 cases of breast
cancer using in situ hybridisation techniques. Gene to
chromosome ratios ≥2 were classiﬁed as ampliﬁcation.
TOP2A deletion (gene to chromosome ratio ≤0.8) or
monosomy (only one signal for both gene and chromosome
in more than 75% of nuclei) were classiﬁed as gene loss.
Results A strong association between TOP2A change and
HR and HER2 status was found. During the ﬁrst 5 years after
diagnosis, the risk of death from breast cancer was
signiﬁcantly higher for cases with HER2 ampliﬁcation
irrespective of TOP2A status.
Conclusions TOP2A copy number change was strongly
associated with HR and HER2 status and as a prognostic
marker TOP2A is probably of limited value.
INTRODUCTION
The HER2 gene has a well-established biological
and clinical role in breast cancer, and the HER2
amplicon on chromosome 17 harbours a number
of genes involved in breast cancer pathophysiology.
Copy number change among these genes is fre-
quently observed though their signiﬁcance remains
to be clariﬁed.1
TOP2A is one of the genes close to HER2 and its
protein product, topoisomerase II α, is the molecular
target of anthracycline treatment. TOP2A ampliﬁca-
tion status has been thought to be linked to response
to treatment. However, data are conﬂicting and, as
yet, unresolved.2 HER2 and TOP2A are associated
with high histopathological grade3 and high prolifer-
ation,4 but the clinical signiﬁcance of TOP2A and its
relationship toHER2 have not been clariﬁed.
The aims of this study were to investigate the fre-
quency of TOP2A copy number change in a well-
characterised cohort of women with breast cancer5
and to correlate TOP2A with HER2 status,
hormone receptor (HR) status and molecular
subtype. A further objective was to explore differ-
ences in breast cancer-speciﬁc survival (BCSS)
according to TOP2A and HER2.
MATERIALS AND METHODS
Study population
A screening programme for early diagnosis of breast
cancer was conducted by the Norwegian Cancer
Registry between 1956 and 1959. The patients devel-
oped breast cancer in a time period with limited access
to adjuvant treatment. None were treated with anthra-
cyclines or trastuzumab. According to the guidelines at
the time of diagnosis, 30.7% patients may have quali-
ﬁed for treatment with tamoxifen. The population has
been described in detail previously.5–7 A total of 1393
women in the underlying population developed breast
cancer in the follow-up period from 1961 to the end
of 2008. Of these, 945 had tissue samples available at
the Department of Pathology and Medical Genetics,
St. Olav’s Hospital, Trondheim, Norway, and 670
were suitable for assessment of TOP2A and HER2
copy number. Survival data were generated after
linkage between the Cause of Death Registry of
Norway and the Norwegian Cancer Registry.
Specimen characteristics
All cases in this study have previously been classi-
ﬁed according to histopathological type and grade
and reclassiﬁed in molecular subtypes according to
ﬁgure 15 using oestrogen receptor (ER),
Figure 1 Classiﬁcation algorithm for molecular subtyping.
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Table 1 Descriptive statistics of the 670 breast cancer cases
TOP2A
normal
TOP2A
amplified
TOP2A
loss
HER2
normal
HER2
amplified Co-amplified
TOP2A loss,
HER2 amplified
TOP2A amplified,
HER2 normal
TOP2A loss,
HER2 normal
Normal TOP2A
and HER2 Total
Number (%) 604 (90.2) 41 (6.1) 25 (3.7) 560 (83.6) 110 (16.4) 32 (4.8) 6 (0.9) 9 (1.3) 19 (2.8) 532 (79.4) 670
Mean age at diagnosis (SD) 73.4 (9.7) 69.5 (9.6) 72.0 (12.5) 74.0 (9.3) 68.3 (11.0) 68.2 (10.1) 69.2 (13.6) 74.3 (5.6) 72.8 (12.3) 74.0 (9.2) 73.1 (9.8)
Median years of follow-up
after diagnosis (IQR))
6.7 (9.4) 5.8 (11.9) 6.4 (5.9) 7.1 (9.1) 4.5 (10.6) 5.1 (12.6) 5.0 (7.9) 6.0 (10.0) 6.7 (8.1) 7.1 (9.2) 6.6 (9.4)
Tumour grade (%)
1 71 (11.8) 1 (2.4) 0 71 (12.7) 1 (0.9) 0 0 1 (11.1) 0 70 (13.2) 72 (10.8)
2 319 (52.8) 16 (39.0) 16 (64.0) 318 (56.8) 33 (30.0) 11 (34.4) 2 (33.3) 5 (55.6) 14 (73.7) 299 (56.2) 351 (52.4)
3 214 (35.4) 24 (58.5) 9 (36.0) 171 (30.5) 76 (69.1) 21 (65.6) 4 (66.7) 3 (33.3) 5 (26.3) 163 (30.6) 247 (36.9)
Tumour size (%)
<2 136 (22.5) 8 (19.5) 5 (20.0) 135 (24.1) 14 (12.7) 5 (15.6) 0 3 (33.3) 5 (26.3) 127 (23.9) 149 (22.2)
2–5 292 (48.3) 15 (36.6) 7 (28.0) 270 (48.2) 44 (40.0) 14 (43.8) 3 (50.0) 1 (11.1) 4 (21.1) 265 (49.8) 314 (46.9)
>5 41 (6.8) 3 (7.3) 5 (20.0) 33 (5.9) 16 (14.6) 2 (6.3) 1 (16.7) 1 (11.1) 4 (21.1) 28 (5.3) 49 (7.3)
Uncertain 135 (22.4) 15 (36.6) 8 (32.0) 122 (21.8) 36 (32.7) 11 (34.4) 2 (33.3) 4 (44.4) 6 (31.6) 112 (21.1) 158 (23.6)
Molecular subtypes (%)
Luminal A 300 (49.7) 7 (17.1) 10 (40.0) 317 (56.6) 0 0 0 7 (77.8) 10 (52.6) 300 (56.4) 317 (47.3)
Luminal B (HER2−) 166 (27.5) 1 (2.4) 6 (24.0) 173 (30.9) 0 0 0 1 (11.1) 6 (31.6) 166 (31.2) 173 (25.8)
Luminal B (HER2+) 37 (6.1) 23 (56.1) 1 (4.0) 0 61 (55.5) 23 (71.9) 1 (16.7) 0 0 0 61 (9.1)
HER2 type 35 (5.8) 8 (19.5) 5 (20.0) 0 49 (44.6) 9 (28.1) 5 (83.3) 0 0 0 49 (7.3)
Five negative phenotype 22 (3.6) 0 0 22 (3.9) 0 0 0 0 0 22 (4.1) 22 (3.3)
Basal phenotype 44 (7.3) 2 (4.9) 3 (12.0) 48 (8.6) 0 0 0 1 (11.1) 3 (15.8) 44 (8.3) 48 (7.2)
Hormone receptor
Positive 503 (83.3) 31 (75.6) 17 (68.0) 490 (87.5) 61 (55.5) 23 (71.9) 1 (16.7) 8 (88.9) 16 (84.2) 466 (87.6) 551 (82.2)
Negative 101 (16.7) 10 (24.4) 8 (32.0) 70 (12.5) 49 (44.5) 9 (28.1) 5 (83.3) 1 (11.1) 3 (15.8) 66 (12.4) 119 (17.8)
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progesterone receptor (PR), Ki67, cytokeratin 5 and epithelial
growth factor receptor (EGFR) 1 as surrogate markers for gene
expression. HER2 status was assessed using chromogenic in situ
hybridisation (CISH).
Assay methods
For the present study, ﬂuorescence in situ hybridisation (FISH)
was employed for detection of TOP2A and chromosome 17
according to the manufacturer`s guidelines. Pretreatment was
done using Histology FISH Accessory Kit, code K5799 (Dako).
The probe mix (VYSIS TOP2A/CEP 17 FISH Probe Kit, code
03N89-020 Abbott Molecular Inc) was applied and denatured
at 73°C for 5 min before hybridisation at 37°C overnight. For
HER2 and chromosome 17, the HER2 CISH pharmDx Kit,
code 109 (Dako), was used and immunostaining for ER (ER
SP1 Cell Marqque 33 mg/mL 1:100) and PR (PR 16 Novocastra
360 mg/mL 1:400) was done in a DakoCytomation Autostainer
Plus (Dako) using Dako REAL EnVision Detection System with
Peroxidase/DAB+, Rabbit/Mouse, code K5007, as previously
described.5
Scoring and reporting
TOP2A gene copy number was evaluated under a ﬂuorescence
microscope (Nikon Eclipse 90i) and HER2 gene under a bright
ﬁeld microscope (Nikon Eclipse 80i) by three of the authors
(AMB, BY and MJE). A minimum of 20 non-overlapping
tumour cell nuclei with signals for both chromosome and gene
were counted in each case. Gene to chromosome ratios ≥2 were
classiﬁed as ampliﬁcation.8–11 TOP2A was considered to be
deleted when the gene to chromosome ratio was ≤0.8.9 12
Cases with only one signal for both gene and chromosome in
more than 75% of all nuclei were recorded as monosomy. In
the analyses, deletion and monosomy were grouped together.
ER and PR were classiﬁed as positive when ≥1% of the tumour
cells showed positive nuclear staining.
Statistical analyses
Follow-up was from breast cancer diagnosis to death from breast
cancer, death from any other cause or to December 31, 2010,
whichever occurred ﬁrst. BCSS was estimated using the Kaplan–
Meier method, and Cox proportional hazards models were used
to estimate risk of death from breast cancer. HRs were calcu-
lated with 95% CIs using Stata V.12.1 IC for Windows (Stata
Corp).
RESULTS
Description of breast cancer cases
Of the 670 cases, 251 (37.5%) died of breast cancer, 314
(46.9%) died of other causes, and at the end of the observation
period, 105 (15.6%) were still alive. Mean age at diagnosis was
73.1 years (SD 9.8; range 41–96 years), and median follow-up
was 6.6 years (IQR 9.42 years). Histopathological grade,
tumour size and molecular subtypes are given in table 1.
Ampliﬁcation and deletion
Table 2 shows ampliﬁcation of TOP2A was found in 41 cases
(6.1%) and monosomy or deletion in 25 (3.7%). HER2 was
ampliﬁed in 110 cases (16.4%) and co-ampliﬁed with TOP2A in
32 cases (4.8%). Of the 25 cases with TOP2A loss, 6 were amp-
liﬁed for HER2. The majority with TOP2A ampliﬁcation
(78.1%) were co-ampliﬁed with HER2, whereas 34.5% of the
HER2 ampliﬁed tumours were either TOP2A ampliﬁed or
showed TOP2A loss. The proportion of HR+ tumours was
higher among cases with TOP2A ampliﬁcation (75.6%) and
TOP2A loss (68.0%) compared with HER2 ampliﬁcation
(55.5%).
Ampliﬁcation and loss according to molecular subtypes
With the exception of 5NP, TOP2A copy number aberrations
were found in all subtypes and were associated with both HR
and HER2 status. A majority of 56.1% of TOP2A ampliﬁed
cases were Luminal B (HER2+). Loss of TOP2A was found
among the HR+ and HER2 negative subtypes (Luminal A and
Luminal B (HER2−)) (64.0%) or HER2 subtype (20.0%). One
of four TOP2A deleted case was Luminal B (HER2+).
BCSS, TOP2A and HER2
The Kaplan–Meier plots in ﬁgures 2 and 3 show BCSS accord-
ing to TOP2A and HER2, respectively, and in ﬁgure 4 the BCSS
according to the status of both genes. Loss of TOP2A in the
absence of HER2 ampliﬁcation did not affect BCSS. The
Kaplan–Meier plots show poorest survival in HER2-ampliﬁed
cases and TOP2A aberrations did not affect this.
Table 2 Number of positive and negative cases for each marker
IHC (%) TOP2A normal TOP2A amplified TOP2A loss Total
HER2+ 72 (11.9) 32 (78.1) 6 (24.0) 110 (16.4)
HER2− 532 (88.1) 9 (21.9) 19 (76.0) 560 (83.6)
ER+ 500 (82.8) 31 (75.6) 17 (68.0) 548 (81.8)
ER− 102 (16.9) 10 (24.4) 8 (32.0) 120 (17.9)
PR+ 361 (59.8) 19 (46.3) 5 (20.0) 385 (57.5)
PR− 243 (40.2) 22 (53.7) 20 (80.0) 285 (42.5)
Ki67 >15% 270 (44.7) 24 (58.5) 13 (52.0) 307 (45.8)
Ki67 >15% 333 (55.1) 17 (41.5) 12 (48.0) 362 (54.0)
CK5+ 115 (19.0) 9 (21.9) 5 (20.0) 129 (19.3)
CK5− 489 (81.0) 32 (78.1) 20 (80.0) 541 (80.8)
EGFR+ 46 (7.6) 1 (2.4) 3 (12.0) 50 (7.5)
EGFR− 558 (92.4) 40 (97.6) 22 (88.0) 620 (92.5)
Total 604 (90.2) 41 (6.1) 25 (3.7) 670 (100.0)
ER, oestrogen receptor; PR, progesterone receptor.
Figure 2 Kaplan–Meier plot. Breast cancer-speciﬁc survival (BCSS)
according to TOP2A. p Value from log-rank test of differences in BCSS
ﬁrst 5 years after diagnosis was 0.02. After 5 years, the p value was
0.4.
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Risk of death from breast cancer, TOP2A, HER2 and HR
status
During the ﬁrst 5 years, risk of death from breast cancer appears
to be signiﬁcantly higher in cases with ampliﬁcation of TOP2A
and HER2 when analysed separately. When compared with no
ampliﬁcation for TOP2A and HER2, respectively, the HR for
TOP2A ampliﬁcation was 2.03 (95% CI 1.22 to 3.360) and for
HER2 was 2.77 (95% CI 1.97 to 3.89). Adjusting for age and
stage did not change the results. For those who survived the ﬁrst
5 years after diagnosis, there were no statistically signiﬁcant dif-
ferences in survival according to gene ampliﬁcation status.
However, as shown in table 3 and ﬁgure 4, TOP2A did not
exert an independent effect on prognosis. Adjusting for HR
status in the Cox proportional hazards model did not change
the results (data not shown). During the ﬁrst 5 years after diag-
nosis, the risk of death from breast cancer was signiﬁcantly
higher for HR+ cases with HER2 ampliﬁcation irrespective of
TOP2A status. Among the HR− cases, the numbers in each cat-
egory were low and the results must be interpreted with
caution.
DISCUSSION
TOP2A gene copy number change in breast cancer is an infre-
quent ﬁnding and its signiﬁcance has been difﬁcult to establish.
In this study of 670 cases of breast cancer with long-term
follow-up, the number of cases with TOP2A ampliﬁcation or
loss was far lower than the number of HER2-positive cases.
However, there was a large proportion of co-ampliﬁcation. In
contrast to others who have found that ampliﬁcation of one or
both genes entails a poorer prognosis compared with cases with
no ampliﬁcation,11 13 14 this study demonstrates that
Figure 3 Kaplan–Meier plot. Breast cancer-speciﬁc survival (BCSS)
according to HER2. p Value from log-rank test of differences in BCSS
ﬁrst 5 years after diagnosis was <0.0001. After 5 years, the p value
was 0.9.
Table 3 Risk of death from breast cancer according to TOP2A and HER2 amplification
Number of cases
Deaths from
breast cancer
Hazard ratio 95% CI
unadjusted
Hazard ratio 95% CI
adjusted for age
Hazard ratio 95% CI
adjusted for stage
TOP2A
Follow-up first 5 years after diagnosis 604 132 1.00 1.00 1.00
Not amplified 41 17 2.03 1.22 to 3.36 2.07 1.24 to 3.47 2.11 1.27 to 3.50
Amplified 25 5 0.91 0.37 to 2.21 0.82 0.33 to 2.01 0.70 0.29 to 1.73
Loss 670 154
TOP2A
Follow-up from 5 years after diagnosis* 359 87 1.00 1.00 1.00
Not amplified 22 5 0.75 0.30 to 1.85 0.74 0.30 to 1.86 1.02 0.41 to 2.54
Amplified 15 5 1.63 0.66 to 4.03 1.93 0.77 to 4.84 1.41 0.56 to 3.52
Loss 396 97
HER2
Follow-up first 5 years after diagnosis 560 105 1.00 1.00 1.00
Not amplified 110 49 2.77 1.97 to 3.89 2.81 1.95 to 4.04 2.66 1.89 to 3.75
Amplified 670 154
HER2
Follow-up from 5 years after diagnosis* 346 83 1.00 1.00 1.00
Not amplified 50 14 0.95 0.54 to 1.67 0.95 0.52 to 1.73 1.04 0.60 to 1.86
Amplified 396 97
HER2 and TOP2A
Follow-up first 5 years after diagnosis 532 100 1.00 1.00 1.00
Normal TOP2A and HER2 38 17 2.61 1.56 to 4.36 2.76 1.63 to 4.69 2.68 1.60 to 4.51
TOP2A change and HER2 amplification 28 5 0.96 0.39 to 2.37 0.89 0.36 to 2.21 0.77 0.31 to 1.90
TOP2A change and HER2 normal 72 32 2.86 1.92 to 4.26 2.81 1.84 to 4.29 2.59 1.74 to 3.87
Amplified HER2, TOP2A normal 670 154
HER2 and TOP2A
Follow-up from 5 years after diagnosis* 328 79 1.00 1.00 1.00
Normal TOP2A and HER2 19 6 0.99 0.43 to 2.28 0.97 0.41 to 2.28 1.44 0.62 to 3.37
TOP2A change and HER2 amplification 18 4 1.07 0.39 to 2.94 1.26 0.45 to 3.50 0.91 0.33 to 2.51
TOP2A change and HER2 normal 31 8 0.92 0.45 to 1.91 0.95 0.44 to 2.04 0.84 0.40 to 1.79
Amplified HER2, TOP2A normal 396 97
*Conditional on surviving the first 5 years CI.
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associations between BCSS and TOP2A copy number change are
not independent of HER2 and HR status.
The most important ﬁnding in this study is the strong associ-
ation between TOP2A copy number change and HR and HER2
status. These markers are well established as prognostic and pre-
dictive factors, and are to a high degree decisive for treatment
after surgery. To the best of our knowledge, few studies have
been designed to examine the prognostic value of TOP2A,
though it has been shown that TOP2A ampliﬁcation affects
BCSS and risk of death from breast cancer15 and that TOP2A
may be a prognostic marker in ER+ breast cancer.14 16
However, when the analyses include HR and HER2 status, the
present study shows that TOP2A has no independent prognostic
impact. TOP2A may still have some modulating effects on prog-
nostication, but this is probably of limited beneﬁt in clinical
practice.
Twenty of twenty-ﬁve cases with TOP2A loss were PR−, and
of these, 12 were ER+. PR negativeness is a predictor of poor
prognosis and appears to be associated with TOP2A loss.
However, in this study, survival tended to be better in PR− cases
with loss of TOP2A compared with cases with normal or ampli-
ﬁed TOP2A (data not shown).
The proportion of ampliﬁcation and co-ampliﬁcation of
TOP2A and HER2 in breast cancer varies between studies.
HER2 ampliﬁcation is reported to be around 15%.2 For
TOP2A, ampliﬁcation varies from 5% to 19%.3 17 18 In
HER2-positive breast cancer, ampliﬁcation of TOP2A varies
from 25% to 42%.1 19 Both ampliﬁcation and deletion of
TOP2A in the absence of HER2 ampliﬁcation have been demon-
strated.3 20 In the present study, 29.1% of the HER2-ampliﬁed
cases were co-ampliﬁed with TOP2A. The proportion of TOP2A
positive tumours in this study was lower than in other studies.2
However, the frequency of HER2 ampliﬁcation is comparable
with others, and this weighs against methodological problems.
Furthermore, a short DNA probe for TOP2A was used to avoid
overlap with HER2.21 This may in part account for the low
number of TOP2A-ampliﬁed cases in this study compared with
previous studies and may reﬂect the true frequency of this
ﬁnding.
Assessment of loss should be carried out with caution in
histopathological sections because nuclear truncation may lead
to a falsely low estimation of copy number. The cut-off for amp-
liﬁcation is usually set at a gene/chromosome ratio of ≥2.0, and
for deletion the cut-off level ranges from 0.5 to 1.0.21 It is pos-
sible that monosomy may have an impact similar to loss of indi-
vidual genes, but this is uncertain. In this study, only four cases
showed deletion and monosomy and deletion were grouped
together.
HER2-positive breast cancer has been shown to be more
aggressive than HER2–negative breast cancer. Co-ampliﬁcation
with other genes, such as STARD3 and GRB7, may contribute to
and possibly strengthen this aggressive behaviour.2 The propor-
tion of ampliﬁcation and co-ampliﬁcation of TOP2A and HER2
in breast cancer is low, and even in a series of 670 patients, the
numbers are too low to draw reliable conclusions. As a prognos-
tic marker, TOP2A is probably of limited value. TOP2A aberra-
tions are strongly associated with HR and HER2 status, and the
importance of these markers in prognostication is still
unchallenged.
Take-home messages
▸ TOP2A gene copy number change is an infrequent ﬁnding in
breast cancer.
▸ There is a strong association between TOP2A copy number
change and hormone receptor and HER2 status.
▸ As a prognostic marker, TOP2A is probably of limited value,
and hormone receptor and HER2 status remain
unchallenged.
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